MIR9-1HG

Across TCGA pan-cancer cohorts, MIR9-1HG Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MIR9-1HG data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MIR9-1HG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR9-1HG expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

DLBC, LIHC, and COAD are the cancer types where MIR9-1HG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
LIHC	OS	Median	All	0.255	0.773	.012	9	view →
COAD	OS	Median	All	0.181	0.806	.002	6	view →
HNSC	OS	Median	All	0.246	0.661	.044	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.680	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MIR9-1HG–DLBC (OS)

Open the DLBC breakdown →